Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function

Archive ouverte

Lehmann, Sylvain | Schraen, Susanna | Vidal, Jean-Sébastien | Delaby, Constance | Blanc, Frédéric | Paquet, Claire | Allinquant, Bernadette | Bombois, Stephanie | Gabelle, Audrey | Hanon, Olivier

Edité par CCSD ; BMJ Publishing Group -

International audience. Objectives : Plasma P-tau181 is an increasingly established diagnostic marker for Alzheimer’s disease (AD). Further validation in prospective cohorts is still needed, as well as the study of confounding factors that could influence its blood level.Methods : This study is ancillary to the prospective multicentre Biomarker of AmyLoid pepTide and AlZheimer’s diseAse Risk cohort that enrolled participants with mild cognitive impairment (MCI) who were examined for conversion to dementia for up to 3 years. Plasma Ptau-181 was measured using the ultrasensitive Quanterix HD-X assay.Results : Among 476 MCI participants, 67% were amyloid positive (Aβ+) at baseline and 30% developed dementia. Plasma P-tau181 was higher in the Aβ+ population (3.9 (SD 1.4) vs 2.6 (SD 1.4) pg/mL) and in MCI that converted to dementia (3.8 (SD 1.5) vs 2.9 (SD 1.4) pg/mL). The addition of plasma P-tau181 to a logistic regression model combining age, sex, APOEε4 status and Mini Mental State Examination improved predictive performance (areas under the curve 0.691–0.744 for conversion and 0.786–0.849 for Aβ+). The Kaplan-Meier curve of conversion to dementia, according to the tertiles of plasma P-tau181, revealed a significant predictive value (Log rank p<0.0001) with an HR of 3.8 (95% CI 2.5 to 5.8). In addition, patients with plasma P-Tau(181) ≤2.32 pg/mL had a conversion rate of less than 20% over a 3-year period. Using a linear regression approach, chronic kidney disease, creatinine and estimated glomerular filtration rate were independently associated with plasma P-tau181 concentrations.Conclusions : Plasma P-tau181 effectively detects Aβ+ status and conversion to dementia, confirming the value of this blood biomarker for the management of AD. However, renal function significantly modifies its levels and may thus induce diagnostic errors if not taken into account.

Suggestions

Du même auteur

Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum

Archive ouverte | Lehmann, Sylvain | CCSD

International audience. Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated...

Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to Dementia

Archive ouverte | Lehmann, Sylvain | CCSD

International audience. Background: Among blood biomarkers, phospho-tau181 (pTau181) is one of the most efficient in detecting Alzheimer disease across its continuum. However, transition from research to routine cli...

Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease

Archive ouverte | Lehmann, Sylvain | CCSD

International audience. Background : Current AT(N) stratification for Alzheimer’s disease (AD) accounts for complex combinations of amyloid (A), tau proteinopathy (T) and neurodegeneration (N) signatures. Understand...

Chargement des enrichissements...